Doximity (DOCS) Q3 2026 earnings review
Solid Beat Masks a Brewing Growth Slowdown
Doximity beat Q3 guidance with $185.1M revenue (+10% YoY) and 60% EBITDA margin, but the real story is in the Q4 guide: just 4% growth. The annual pharma buying season was disrupted by MFN (Most Favored Nation) negotiations between 16 of the top 20 pharma companies and the White House, delaying bookings and leaving budgets partially unreleased. January bookings hit the highest growth rate since IPO—confirming delayed, not lost, demand. Management expects to exit calendar 2026 as a double-digit grower, partly fueled by a new commercial AI product launching later this year. A new $500M buyback was authorized. Net income fell 18% YoY to $61.6M as rising SBC and AI infrastructure costs weighed on profitability.
🐂 Bull Case
January pharma bookings hit the highest growth rate since IPO. Management attributes the Q4 slowdown to MFN-driven budget freezes, not competitive losses. Once 2026 plans are finalized, unreleased funds should flow to Doximity given its industry-leading 10:1 ROI.
Over 300,000 prescribers used AI products in Q3. 100+ health systems signed AI contracts covering 180,000 clinicians. CEO Tangney pointed to paid healthcare search—55% of digital healthcare marketing spend per eMarketer—as a large, unaddressed market. A commercial AI product is planned for later this year with zero AI revenue in current guidance.
🐻 Bear Case
Revenue growth has decelerated from 25% (25Q3) to 10% (26Q3), with Q4 guided at just 4%. Full-year guidance midpoint held flat despite the Q3 beat, implying management absorbed the upside. The market growth assumption dropped to ~5% for calendar 2026, down from the prior 5-8% range.
GAAP net income fell 18% YoY even as revenue grew 10%. Non-GAAP gross margin compressed 180bps to 91.5%. SBC surged 73% YoY to $33.5M (18.1% of revenue vs 11.5% a year ago). AI infrastructure costs are rising with no associated revenue yet, and the 50% EBITDA margin was framed as a floor, not a target.
⚖️ Verdict: ⚪
Neutral. The Q3 beat was solid and AI traction is impressive, but the sharp Q4 deceleration and flat annual guidance raise questions about near-term momentum. The MFN disruption explanation is credible—January bookings confirm it—but execution on the second-half recovery and AI commercialization must materialize before the growth narrative rebuilds.
Key Themes
MFN-Driven Pharma Budget Freeze Disrupts Buying Season
16 of the top 20 pharma companies signed Most Favored Nation deals with the White House between late December and early January, causing unprecedented disruption to the annual buying season. Multiple customers deployed a lower percentage of budgets upfront than usual, and deals typically signed by December 31 were pushed into January. Management described this as an anomaly, not a structural shift, but it directly caused the weak Q4 guide (4% growth) and means calendar 2026 is off to a slower start than usual. The silver lining: January pharma bookings growth was the highest since IPO.
AI Platform Adoption Accelerating Rapidly
Over 300,000 unique prescribers used AI products in Q3—roughly 20% of the network's physicians—in the first full quarter post-Pathway acquisition. DocsGPT active prescribers queried the tool 4x per week on average in January. A head-to-head trial of 1,300 high-prescribing physicians found doctors preferred DocsGPT at 2x the rate of the nearest competitor, particularly on drug-related questions. Over 100 top health systems have signed AI contracts covering 180,000 clinicians. Peer Check now has 10,000+ physician experts—more than the largest legacy medical publisher's ~7,000. AI is not yet monetized; commercial products are expected later this calendar year.
DocDynamic Integrated Programs Gaining Share
DocDynamic (AI-optimized integrated programs) accounted for ~45% of Q3 bookings, up from 18% a year ago and over 40% in Q2. These multi-module programs drive larger deal sizes, better client ROI, and more predictable revenue. The shift toward integrated programs has smoothed the historical year-end 'budget flush' into more even spending across the year.
Network Scale and Engagement at Record Highs
Doximity surpassed 3 million registered members, covering 85%+ of US physicians and two-thirds of all NPs and PAs. All engagement cohorts (quarterly, monthly, weekly, daily) hit fresh highs. Newsfeed had 1M+ quarterly active prescribers, and workflow reached a record 720,000—the largest sequential gain ever. Dialer was ranked #1 telehealth platform by health system CIOs for the fifth consecutive year. During recent snowstorms, over 700,000 telehealth visits were served in a single day.
Rising SBC and AI Costs Pressuring GAAP Profitability
Stock-based compensation surged 73% YoY to $33.5M in Q3 (18.1% of revenue vs 11.5% a year ago), driven by Pathway acquisition grants and AI talent retention. GAAP net income fell 18% YoY to $61.6M despite 10% revenue growth. Non-GAAP gross margin compressed 180bps to 91.5% from 93.3% due to higher AI infrastructure costs. Management guided the 50% EBITDA margin as a floor and acknowledged AI costs will continue rising, though they expect unit economics to improve over time as they scale.
Net Revenue Retention Declining
NRR dropped to 112% from 117% in 25Q3 and 118% in both 26Q1 and 26Q2. Top-20 NRR fell to 117% from 122% a year ago. While still healthy, the declining trajectory signals slowing same-customer expansion. Management attributes this partly to the MFN-driven budget delays rather than structural churn, but the trend bears monitoring—especially as the Q4 guide implies further pressure.
Paid Healthcare Search: The Next TAM Expansion
CEO Tangney highlighted that 55% of healthcare digital marketing spend goes to search (per eMarketer), a market Doximity has never participated in. The commercial AI product launching later this year is expected to tap into clients' innovation, upsell, and search budgets. Management declined to elaborate on specific plans but signaled significant client excitement. This represents a meaningful TAM expansion beyond the current newsfeed and workflow advertising channels.
Aggressive Capital Return via Buybacks
Doximity repurchased $196.8M of shares in Q3 alone—more than total FY25 buybacks of $120.3M. A new $500M open-ended buyback authorization was approved on top of the $83M remaining. YTD repurchases total $341.1M. Cash, equivalents, and marketable securities stood at $735M at quarter end, down from $878M in Q2, reflecting the accelerated pace. Management characterized buybacks as a valuable use of cash above reinvestment needs.
CFO on Medical Leave Creates Governance Uncertainty
CFO Anna Bryson is on medical leave. Audit Committee Chair Tim Cabral (former Veeva CFO) stepped in for the earnings call. While the transition appeared smooth, the absence of the CFO during a critical period—with a complex MFN-related bookings disruption and AI investment ramp—adds a layer of execution uncertainty. No timeline for return was provided.
Other KPIs
Up 9.8% YoY from $168.6M. Decelerating from 23.2% in 26Q2 and 15.2% in 26Q1. Beat the high end of guidance ($181M) by ~$4M. Nine-month revenue of $499.5M is up 15.6% YoY. The deceleration from Q2's 23% is partly explained by the shift in upsell timing toward integrated programs (pulling revenue into Q2), but Q4's 4% guide confirms a real slowdown from MFN disruption.
Up 9.2% YoY from $102.0M. Margin essentially flat at 60.2% vs 60.5%. Beat the high end of guidance ($104M) by $7.4M. However, the Q4 guide implies a sharp margin drop to ~44.6% ($64M on $143.5M), driven by higher AI infrastructure costs and lower revenue. Full-year margin guided at 55%, with 50%+ framed as a floor going forward.
Down 7.7% YoY from $63.4M, primarily due to a $27.6M increase in accounts receivable (vs $13.0M a year ago) and higher deferred contract cost investments ($6.7M vs $5.9M). Nine-month FCF of $210.2M is up 23.8% YoY ($169.8M). Operating cash flow of $60.9M was down 6.6% YoY. The AR spike warrants monitoring—it could reflect the delayed bookings/billing cycle from MFN disruption.
Up ~10% YoY from 115. Growth has decelerated from 21% (25Q3, 114 to now) and 17% (26Q1, 120). These customers accounted for 84% of total revenue. The slower pace of large customer additions aligns with the broader growth deceleration and MFN-driven budget conservatism among top pharma accounts.
Down from $878M at end of Q2, primarily driven by $196.8M in share repurchases in Q3. Balance sheet remains strong with no debt. Cash and equivalents alone dropped to $64.8M from $169.2M, but $670.3M in marketable securities provides ample liquidity.
Guidance
Decelerating sharply. The midpoint ($143.5M) implies ~3.8% YoY growth, down from 9.8% in Q3 and the year-ago Q4's $138.3M (which itself grew 17.1%). This reflects the MFN-driven delayed bookings and lower upfront budget deployment. Management expects the growth rate to improve through calendar 2026, targeting a double-digit exit rate, supported by unreleased pharma budgets, stabilized MFN dynamics, and a new commercial AI product.
Stable. Midpoint of $643M represents ~12.7% YoY growth (from $570.4M in FY25), essentially unchanged from prior guidance of $640-$646M despite the Q3 beat. The Q3 revenue outperformance was absorbed by the lower Q4 outlook. Prior guidance at Q1 was $628-$636M (raised from initial $619-$631M), then raised at Q2 to $640-$646M.
Margin compression. The midpoint ($64M) implies a ~44.6% margin, a significant step-down from 60.2% in Q3 and 50.4% in the year-ago Q4. This reflects both lower revenue leverage and higher AI infrastructure/Peer Check investment costs. The sequential decline from $111.4M to $64M is striking and highlights the seasonally weak Q4 revenue combined with rising cost investments.
Stable at 55% margin. Midpoint of $356M is in line with prior guidance of $351-$357M. Despite Q3's 60% margin, the full-year is held at 55% as AI and Peer Check investments ramp in Q4. Management introduced a 50%+ annual EBITDA margin floor for future periods, signaling willingness to invest more heavily in AI while protecting a minimum profitability threshold.
Key Questions
AI Commercialization Details
You plan to launch a commercial AI product 'later this year' targeting search budgets. What form will this take—sponsored answers, premium placements, branded content within DocsGPT? What pricing model are you considering, and what's the revenue ramp assumption for FY27?
NRR Trajectory and MFN Recovery
NRR dropped from 118% to 112% in one quarter. How much of this is MFN-driven timing versus structural? What NRR level should investors expect once MFN effects normalize—can you return to 118%+, or has the growth-from-existing-customers rate structurally slowed?
AI Unit Economics at Scale
Non-GAAP gross margin fell 180bps YoY to 91.5%, attributed to AI infrastructure. With 300,000 users querying 4x/week and growing, what is the current cost-per-query trend? At what user count does AI cost become material enough to threaten the 50% EBITDA floor before commercialization begins?
Competitive Moat in Medical AI
You highlighted Peer Check's 10,000 experts vs the leading publisher's 7,000. But large well-funded players are entering clinical AI aggressively. Beyond peer review, what technical or data moats prevent a well-resourced competitor from replicating your drug reference and journal access advantages?
CFO Succession Planning
Anna Bryson's absence was not addressed beyond 'medical leave.' What is the timeline for her return? Is there a formal interim CFO appointment, or is Tim Cabral's role limited to earnings calls? How does this affect strategic decision-making during a pivotal AI investment period?